Danaher (DHR) Stock on December 1, 2025: Q3 Beat, Legal Probes and Fresh Price Targets – Is the Premium Still Worth Paying?
Danaher Corporation (NYSE: DHR) enters December 2025 trading around the mid‑$220s per share, a high‑quality life‑sciences and diagnostics name that continues to command a premium valuation — and attract both bullish analysts and governance‑focused law firms. TS2+1 Below is a